Table 3.
Hemagglutination inhibition (HI) antibody titers in the intradermal (ID) group (n = 64) compared with intramuscular (IM) group (n = 62) pre-vaccination and 4 weeks post-vaccination in patients who had no previous vaccination containing influenza A(H1N1)pdm09 virus or no history of influenza A(H1N1)pdm09 infection.
| H1N1pdm09 |
H3N2 |
B |
||||
|---|---|---|---|---|---|---|
| ID | IM | ID | IM | ID | IM | |
| Pre-vaccination GMT (95% CI) | 14.0(10.1-19.4) | 12.9(9.6-17.4) | 32.6(22.8-46.6) | 25.0(17.6-35.5) | 9.2(7.1-11.9) | 8.5(6.7-10.7) |
| P-value | 0.789 | 0.307 | 0.835 | |||
| Post-vaccination GMT(95% CI) | 74.2 (51.6-106.6) | 95.7 (66.7-137.2) | 165.3 (117.0-233.5) | 127.9 (88.9-184.2) | 21.3(15.5-29.4) | 19.1(13.6 -26.8) |
| P-value | 0.316 | 0.296 | 0.517 | |||
| Seroconversion factor* (95% CI) | 12.4(8.3-16.5) | 19.9(12.1-27.7) | 17.0(9.6-24.2) | 15.6(9.0-22.2) | 4.3(2.9-5.7) | 5.8(3.4-8.2) |
| P-value | 0.168 | 0.935 | 0.490 | |||
| Seroconversion rate* %, (95% CI) | 53.1(41.1-64.8) | 66.1(53.7-76.7) | 60.9(48.7-72.0) | 56.5(44.1-68.1) | 17.2(9.7-28.4) | 17.7(10.0-29.2) |
| P-value | 0.137 | 0.609 | 0.935 | |||
| Pre-vaccination seroprotection rate%, (95% CI) | 23.4(14.6-35.2) | 27.4(17.8-39.7) | 54.7(42.6-66.3) | 40.3(29.0-52.8) | 15.6(8.5-26.6) | 12.9(6.4-23.7) |
| P-value | 0.608 | 0.107 | 0.662 | |||
| Post-vaccination seroprotection rate*%, (95% CI) | 67.2(55.0-77.5) | 79.0(67.2-87.5) | 82.8(71.6-90.3) | 77.4(67.2-87.5) | 37.5(26.7-49.8) | 33.9(23.3-46.3) |
| P-value | 0.134 | 0.448 | 0.671 | |||
*
Committee for Proprietary Medicinal Products (CPMP) criteria4: Seroconversion factor > 2.0, Seroconversion rate > 30, seroprotection rate > 60.